CLINICAL_TRIALS
trial_result
· 2025-03-27
Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention [Phase 2, Phase 3]
Summary
Pfizer's oral zavegepant was evaluated for migraine prevention in Phase 2/Phase 3 trials. The study was terminated and results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: Migraine | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2025-03-27